Introduction
============

In women with early breast cancer (BC), a pathological complete response (pCR) after neoadjuvant chemotherapy is reported to be associated with improvements in the disease-free survival (DFS) and overall survival (OS) [@R6429462-1] ,  [@R6429462-2] . This is the main reason why pCR is currently being discussed as a surrogate marker for the effectiveness of chemotherapy [@R6429462-3] ,  [@R6429462-4] ,  [@R6429462-5] . However, therapy response and outcomes for patients differ depending on the tumor biology. HER2-positive and triple-negative BC patients not only achieve pCR more frequently than those with luminal disease, but also have the strongest association with a better prognosis when no residual cancer is found at surgery [@R6429462-1] ,  [@R6429462-2] ,  [@R6429462-6] . This in turn means that in women with hormone receptor-positive, HER2-negative disease, identifying those patients who are more likely to benefit from chemotherapy is an unresolved issue.

In order to make a decision for or against chemotherapy in this patient population, a mixture of prognostic and predictive factors has usually been taken into consideration, with the likelihood of a treatment response being weighed up against the prognosis for the individual patient. Tumor size, lymph-node status, tumor grade, estrogen receptor (ER) status, progesterone receptor (PR) status, and in some institutions Ki-67 and uPA/PAI-1 status are the main factors in clinical routine work that are used to assess the need for chemotherapy [@R6429462-7] ,  [@R6429462-8] ,  [@R6429462-9] ,  [@R6429462-10] . Multigene assays are also being incorporated into clinical routine work to estimate the patientsʼ prognosis and spare patients who have an excellent prognosis the need to undergo chemotherapy [@R6429462-11] ,  [@R6429462-12] ,  [@R6429462-13] . This approach was recently confirmed by the TailorX study [@R6429462-14] . Patients were eligible for randomization within the trial (chemotherapy and endocrine treatment vs. endocrine treatment alone) if they had a hormone receptor-positive and HER2-negative breast cancer and an intermediate recurrence risk as assessed by a 21-multigene assay (for this study defined as 11 -- 25). The tumors also had to be node-negative. The study showed that endocrine therapy alone is as effective as chemotherapy and endocrine treatment. For women under the age of 50, however, a potential additional benefit from chemotherapy could not be excluded [@R6429462-14] .

However, it is still not clear from this trial which individual patients will benefit from chemotherapy. In addition, patients who had a recurrence score over 25 did not undergo randomization in the TailorX study but were assigned to receive endocrine therapy and chemotherapy. This group of patients had the poorest prognosis in the study [@R6429462-14] , and it is unclear whether this group benefits from chemotherapy at all.

A new biomarker indicating the probability of pCR in patients with hormone receptor-positive HER2-negative breast cancer could potentially be helpful in identifying a patient population in which the patients and physicians would feel comfortable with an indication for neoadjuvant chemotherapy. The aims of the present survey carried out among physicians were therefore to investigate whether the probability of achieving pCR in hormone receptor-positive, HER2-negative BC patients may encourage physicians to recommend neoadjuvant chemotherapy; and to establish a cut-off level for a pCR rate that most physicians would consider high enough to serve as an indication for the treatment.

Methods
=======

Data acquisition
----------------

An anonymized online survey was conducted using SurveyMonkey (San Mateo, California, USA) in German. The study was conducted in Germany in May 2018 and included physicians who were known as members of national guideline committees, heads of breast cancer centers, frequent recruiters in clinical trials, or running private practices. The e-mail addresses for the survey were obtained by Internet research or were known from the authorsʼ personal communications.

The link to the survey was sent to a total of 493 medical professionals by e-mail and was open for 8 days (May 17 to May 24, 2018). The recipients were reminded to participate in the survey three times (on May 18, 23, and 24, 2018). The data were completely anonymized before the analysis and no personal data were permanently stored.

The survey comprised 13 questions and one comment field. Seven items captured the participantsʼ characteristics ( [Table 1](#TB6429462-1){ref-type="table"} ) and six items collected data about which tumor and patient characteristics might guide the physician with regard to making a decision for or against chemotherapy. This was done by asking about a specific case intended to resemble a patient for whom it is unclear whether she should be treated with chemotherapy: a 60-year-old patient (with no further comorbidities) with an invasive ductal carcinoma 2.5 cm in diameter, G2, one positive lymph node, estrogen receptor-positive, progesterone receptor-positive, HER2-negative ( [Table 2](#TB6429462-2){ref-type="table"} ).

###### 

**Table 1**  Characteristics of participants.

  Question                                                                         n     Mean (SD) or %
  -------------------------------------------------------------------------------- ----- ----------------
  How old are you (in years)?                                                      113   50.5   (8.04)
  Are you a decision-maker on the oncologic treatment of breast cancer patients?         
  Yes                                                                              107   94.7
  No                                                                               6     5.3
  Total                                                                            113   100.0
  Where do you work?                                                                     
  Hospital                                                                         82    72.6
  Practice                                                                         27    23.9
  Other                                                                            4     3.5
  Total                                                                            113   100.0
  Are you a member of a guideline group (S3, AGO, ABC, NCCN, etc.)?                      
  Yes                                                                              40    35.4
  No                                                                               73    64.6
  Total                                                                            113   100.0
  What is your specialist discipline?                                                    
  Gynecology                                                                       95    84.1
  Oncology                                                                         16    14.2
  Not working as a physician                                                       1     0.9
  Other                                                                            1     0.9
  Total                                                                            113   100.0
  Are you a medical specialist?                                                          
  Yes                                                                              107   94.7
  No                                                                               6     5.3
  Total                                                                            113   100.0
  How many years of work experience do you have?                                         
  Less than 10 years                                                               4     3.5
  Between 10 and 20 years                                                          35    31.0
  More than 20 years                                                               74    65.5
  Total                                                                            113   100.0

###### 

**Table 2**  Survey results on decision-making criteria for chemotherapy.

  Question                                                                                                                                                                                   n     \%
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----- -------
  **In a 60-year-old patient (with no further comorbidities) with an invasive ductal carcinoma 2.5 cm in diameter, G2, one positive lymph node, ER-positive, PR-positive, HER2-negative:**         
  Does your decision regarding chemotherapy depend on the expression of ER (in %)?                                                                                                                 
  No                                                                                                                                                                                         48    42.5
  Yes                                                                                                                                                                                        65    57.5
  Total                                                                                                                                                                                      113   100.0
  Does your decision regarding chemotherapy depend on the expression of PR (in %)?                                                                                                                 
  No                                                                                                                                                                                         61    54.0
  Yes                                                                                                                                                                                        52    46.0
  Total                                                                                                                                                                                      113   100.0
  Does your decision regarding chemotherapy depend on the expression of Ki-67 (in %)?                                                                                                              
  No                                                                                                                                                                                         11    9.7
  Yes                                                                                                                                                                                        102   90.3
  Total                                                                                                                                                                                      113   100.0
  If you knew how high the probability of achieving a pCR through neoadjuvant chemotherapy is, would you use this information to make a decision for or against neoadjuvant chemotherapy?          
  No                                                                                                                                                                                         18    15.9
  Yes                                                                                                                                                                                        95    84.1
  Total                                                                                                                                                                                      113   100.0
  How high should the probability of achieving pCR be in order to perform neoadjuvant chemotherapy (e.g., four cycles of epirubicin/cyclophosphamide followed by 12 cycles of paclitaxel)?         
  At least 5%                                                                                                                                                                                3     2.7
  At least 10%                                                                                                                                                                               12    10.6
  At least 20%                                                                                                                                                                               29    25.7
  At least 30%                                                                                                                                                                               29    25.7
  At least 40%                                                                                                                                                                               21    18.6
  At least 50%                                                                                                                                                                               19    16.8
  Total                                                                                                                                                                                      113   100.0
  Can you imagine that information about the probability of pCR could influence treatment decision-making, as with a multigene assay?                                                              
  No                                                                                                                                                                                         4     3.5
  Yes, in combination with a multigene assay                                                                                                                                                 28    24.8
  Yes, even independently of a multigene assay                                                                                                                                               54    47.8
  Possibly, not yet certain                                                                                                                                                                  27    23.9
  Total                                                                                                                                                                                      113   100.0

Statistical methods
-------------------

The responses were evaluated descriptively by using means and standard deviation or percentage and number of participants. Analyses were performed with IBM SPSS Statistics for Windows, Version 21.0 (IBM Corporation, Armonk, New York, USA).

Results
=======

Participants
------------

E-mail delivery failed in a total of 32 cases (6.5%), so that the final group consisted of 461 recipients, of whom 113 (24.5%) responded to the survey ( [Fig. 1](#FI6429462-1){ref-type="fig"} ).

![ Participant flow chart.](10-1055-a-0642-9462-i6429462gf01){#FI6429462-1}

The participants had an average age of 50.5 years (standard deviation 8.0) and had work experience of more than 10 years in 96.5% of cases. Their workplaces were a hospital setting in 72.6% of cases (n = 82) and in a practice setting in 23.9% (n = 27). Most participants were gynecologists (84.1%; n = 95) and 14.2% (n = 16) were oncologists. A total of 107 participants (94.7%) stated that they were board-certified in their specialty and the same number confirmed that they were responsible for making treatment decisions at their institution. Finally, 40 participants (35.4%) were members of a national or international guideline committee. The participantsʼ characteristics are summarized in [Table 1](#TB6429462-1){ref-type="table"} .

Chemotherapy decision criteria
------------------------------

For the case described in the Methods section for each of the parameters ER, PR, and Ki-67, it was asked whether the magnitude of the expression in percentage assessed by immunohistochemistry (0 -- 100%) had an influence on decision-making for or against neoadjuvant chemotherapy. The respondents stated that the magnitude of ER and PR expression would influence that decision in the specific case in 57.5% (n = 65) and 46.0% (n = 52) of cases, respectively. Ki-67 expression would have an influence on chemotherapy decision-making for 102 (90.3%) of the participants ( [Table 2](#TB6429462-2){ref-type="table"} and [Fig. 2](#FI6429462-2){ref-type="fig"} ).

![ Survey results on chemotherapy decision criteria.](10-1055-a-0642-9462-i6429462gf02ad){#FI6429462-2}

In relation to the probability of pCR, a total of 95 participants (84.1%) stated that they would take this measure into account in decision-making concerning neoadjuvant chemotherapy. With regard to the probability of pCR, 2.7% (n = 3) and 10.6% (n = 12) of the participants would require pCR rates of at least 5 and 10%, respectively, while 25.7% (n = 29) would be satisfied with a probability of 20% and a further 25.7% (n = 29) would be satisfied with a pCR rate of 30%. Thus, 64.7% would be satisfied with a pCR rate of 30% ( [Table 2](#TB6429462-2){ref-type="table"} and [Fig. 2](#FI6429462-2){ref-type="fig"} ).

In total, 24.8% of respondents were able to imagine that information about the probability of pCR would be capable of influencing chemotherapy decision-making when combined with a multigene assay. In contrast, in the opinion of 47.8% this might be the case even independently of a multigene assay ( [Table 2](#TB6429462-2){ref-type="table"} and [Fig. 2](#FI6429462-2){ref-type="fig"} ).

Discussion
==========

The online survey conducted shows that the majority of physicians are able to imagine using the probability of pCR as a marker in decision-making for or against chemotherapy. It also shows that approximately two thirds of the participating physicians would be satisfied with a pCR probability of 30% or lower, meaning that the physicians would accept treating seven out of 10 patients with chemotherapy without achieving a pCR.

The survey inquired about a patient with hormone receptor-positive, HER2-negative BC -- a group of patients in whom the correlation between pCR and prognosis is not as well established as in triple-negative or HER2-positive BC patients [@R6429462-1] ,  [@R6429462-2] . There are also only limited data regarding the extent to which the quantitative expression of ER, PR, and Ki-67 influences pCR rates. ER, PR, and Ki-67 are usually assessed with immunohistochemistry, and expression is reported in a quantitative fashion; however, when it comes to correlation with pCR, these markers are used as dichotomous variables (positive/negative). Hormone receptor-positive patients are reported to have fairly low pCR rates, while hormone receptor-negative patients have fairly high pCR rates [@R6429462-1] ,  [@R6429462-2] ,  [@R6429462-6] ,  [@R6429462-15] ,  [@R6429462-16] ,  [@R6429462-17] . In addition -- specifically in luminal-like tumors -- there are several reports that have correlated increasing Ki-67 expression with increasing pCR rates [@R6429462-6] ,  [@R6429462-18] ,  [@R6429462-19] .

In clinical practice, cut-off levels are used to categorize breast cancer patients into positive versus negative. ER and PR were initially categorized to distinguish between women who benefit from endocrine therapy from those who do not, and the levels have varied from 10% through 1 -- 10% to ≥ 1% over the years [@R6429462-20] ,  [@R6429462-21] ,  [@R6429462-22] . These cut-off levels were therefore also used to learn about the correlation with chemotherapy responsiveness [@R6429462-23] .

The present survey shows that most physicians would be satisfied with a 30% rate of pCR. To meet that criterion, it is not known which cut-off levels for ER, PR, and Ki-67 should be used. Including these markers additionally to conventional patient and tumor characteristics might be helpful for exploring this topic further.

Other studies have also examined decision-making parameters for neoadjuvant chemotherapy in hormone receptor-positive patients. A large prospective noninterventional study in postmenopausal women showed that age, body mass index, tumor grade, HER2 status, and the fact that patients were taking concomitant medication were influencing factors in relation to decision-making for or against neoadjuvant chemotherapy [@R6429462-24] . Information about the patientʼs pCR status could further add to this list of influencing factors.

Independently of the prediction of pCR, the question remains of how to estimate the effect of chemotherapy and/or pCR on the prognosis. While an association between pCR and prognosis has been well described, some studies have shown that there may be subgroups of patients who do not benefit as much from chemotherapy as others, even among those with triple-negative findings [@R6429462-1] ,  [@R6429462-25] . Two studies have described such an effect for *BRCA* mutation carriers [@R6429462-26] ,  [@R6429462-27] . However, it must be noted that other studies have not observed this effect [@R6429462-28] ,  [@R6429462-29] . On the other hand, there is evidence from the GeparSepto study that a benefit of chemotherapy vs. another treatment may be conferred even in a subgroup in which the chemotherapy comparison does not show a difference in pCR rates [@R6429462-30] . Additionally it is even hypothesized that in some subgroups such as lobular breast cancer chemotherapy might be even harmful [@R6429462-31] . There are several predictive methods that assess the prognosis either using clinical variables or multigene assays, or both together [@R6429462-14] ,  [@R6429462-32] ,  [@R6429462-33] ,  [@R6429462-34] ,  [@R6429462-35] ,  [@R6429462-36] . However, these predictors have not included pCR or the effects of neoadjuvant chemotherapy in the models.

One strength of the present survey is not only that approximately 25% of the recipients participated in the survey, but also that some 95% of them were board-certified. The results thus represent the views of physicians with substantial experience. A large number of guideline committee members also appear to have taken part in the survey. The study is of course only a survey among physicians and does not reflect the actual behavior of physicians using the probability of pCR as a decision-making criterion. However, such a marker is not available at the moment, so that considerations at present can be only hypothetical. It should be noted that physicians were only asked about their opinion of which pCR rate they would require for a decision in favor of neoadjuvant therapy, and no patients were included in the survey. However, it is known that the size of the treatment effect required may differ widely between physicians and patients when they are asked about a case and about possible treatment effects [@R6429462-37] ,  [@R6429462-38] .

Conclusion
==========

This survey shows that 84% of physicians with long-term experience would welcome the possibility of using the probability of pCR in decision-making concerning neoadjuvant chemotherapy in a patient with hormone receptor-positive, HER2-negative breast cancer. The majority of the respondents appeared to be satisfied with a cut-off level of a pCR probability around 30%. However, further research will be needed in order to establish this type of pCR probability marker and the way in which it could be used in clinical practice.
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